论文部分内容阅读
自1986年Murry等[1]首先提出心肌缺血预适应(ischemicpreconditioning,IPC)的概念以来,缺血预适应的细胞和分子机制的动物实验和临床研究得到了广泛开展。其限制心肌梗死面积、减少再灌注心律失常发生和改善心室收缩功能的有效作用日益受到关注,也给心血管疾病康复机制和方法带
Since the concept of myocardial ischemic preconditioning (IPC) was first proposed by Murry et al [1] in 1986, animal experimental and clinical studies on the cellular and molecular mechanisms of ischemic preconditioning have been extensively conducted. Its effective role of limiting myocardial infarct size, reducing reperfusion arrhythmia and improving ventricular systolic function is receiving increasing attention and giving cardiovascular rehabilitation mechanisms and methods